ANPP (Algeria)

The Agence Nationale des Produits Pharmaceutiques (ANPP) is Algeria’s autonomous national authority for human medicines, biologicals, vaccines, medical devices, in vitro diagnostics, reagents, cosmetics, controlled substances, and pharmacy practice oversight. It consolidates functions that were previously dispersed across the Laboratoire National de Contrôle des Produits Pharmaceutiques (LNCPP), the former Direction de la Pharmacie, and the industrial pharmaceutical portfolio. ANPP became operational in 2020 following the 2018 health-law reforms and organizational decrees that modernized the regulatory system.

ANPP reports to the Ministry of Pharmaceutical Industry, a portfolio that is institutionally separate from the Ministry of Health. This ministerial separation—unique in the region—was formalized to reinforce industrial policy, domestic production, and supply security while retaining technical coordination with the Ministry of Health for public-health programs and clinical-policy interfaces. ANPP is headquartered in Algiers (Cité Sahraoui Mohamed, Bir Mourad Raïs) and operates with a Director General appointed by presidential decree, supported by a multi-ministerial and scientific board.

Strategically, ANPP has grown quickly, now employing a large technical staff and operating the LNCPP as Algeria’s state quality-control laboratory. It participates in international harmonization initiatives, is a WHO Listed Authority candidate, and engages in the WHO Prequalification Collaborative Registration Procedure and African regulatory work sharing. The Commission d’Enregistrement des Produits Pharmaceutiques provides marketing-authorization decisions within ANPP’s statutory framework. Sponsors targeting Algeria’s nearly 45 million population should expect an authority committed to regulatory convergence and domestic manufacturing, with enhanced reliance tools and formalized post-market oversight.

Algeria applies Bonnes Pratiques de Fabrication (BPF) requirements that align with PIC/S Good Manufacturing Practice and the EU GMP structure in EudraLex Volume 4. For active substances, ICH Q7 principles are referenced by ANPP reviewers as the benchmark for quality and compliance. Sponsors should expect ANPP to verify that both finished dosage and API sites demonstrate consistent adherence to internationally harmonized GMP expectations, including data integrity and lifecycle validation.

Foreign manufacturers may submit recent EU or PIC/S inspection outcomes as supportive evidence; however, ANPP may still request additional inspections or targeted evidence depending on product risk, sterile status, and complaint history. For sterile and aseptic processes, alignment with PIC/S Annex 1 is explicit in dossier reviews and on-site verifications. Where WHO guidelines are used as a reference, ANPP points to the consolidated principles in WHO GMP TRS 1044 for interpretation across facilities and contractors.

Process validation is expected to cover the full equipment lifecycle, including installation, operation, and performance qualification consistent with IQ, OQ, PQ. Validation master plans, cleaning validation for shared equipment, computerized system controls, and environmental monitoring programs are routinely sampled during inspections. The site master file should clearly map quality responsibilities for contract manufacturers, testing laboratories, and distributors operating in Algeria.

• Site Master File reflecting product families released to Algeria and their critical utilities and flows
• BPF certificate or recent PIC/S/EU GMP evidence tied to the specific legal entity and address
• Validation Master Plan with executed IQ/OQ/PQ summaries for critical equipment and computerized systems
• Aseptic process simulations and contamination-control strategy for sterile products aligned to Annex 1
• API quality statements and supplier oversight aligned to ICH Q7, including change-control history

Marketing authorization in Algeria follows two principal routes: the Autorisation de Mise sur le Marché (AMM) for foreign-origin or centrally assessed products, and the Décision d’enregistrement for products manufactured locally. Both routes use a CTD-aligned dossier, with administrative and labeling components in French. ANPP encourages reliance on recognized assessments but requires national decisions grounded in Algerian law.

For generics, bioequivalence is the default evidence standard, while biosimilars require analytical similarity and comparability data commensurate with product complexity. Language, pharmacopoeial standards, and proposed price must be internally consistent across the administrative form, labeling proofs, and quality modules. Timelines depend on completeness and risk class; the authority clock may pause for targeted clarifications, GMP issues, or pricing queries.

Public-health priorities—such as essential medicines shortages or epidemic response—qualify for expedited handling when dossiers are complete and benefit-risk is clear. Where WHO Prequalification or stringent regulatory approvals are available, ANPP may apply facilitated review while maintaining national batch-testing requirements and post-market conditions.

ANPP implements facilitated regulatory pathways that leverage trusted assessments without abdicating national decision-making. Within the African Medicines Regulatory Harmonization (AMRH) ecosystem, Algeria participates in technical work sharing and convergence activities, enabling reviewers to compare and adopt elements of prior evaluations alongside Algerian specifics such as language, pricing, and local pharmacovigilance. This reduces duplication while maintaining statutory obligations under Law 18-11.

For vaccines and priority therapeutics, ANPP participates in the WHO Prequalification Collaborative Registration Procedure. Under CRP, manufacturers authorize WHO to share assessment and inspection outcomes with ANPP, and the authority conducts an abridged review focused on national context and any residual risks. Sponsors should plan their dossier, labeling, and certificates so that the CRP package and Algerian administrative forms are congruent. Learn more about WHO Prequalification when structuring a reliance-ready file.

Bilateral reliance may reference assessments from the European Medicines Agency and certain EU national competent authorities such as ANSM (France) or AEMPS (Spain). These references are supportive, but ANPP still verifies country-of-origin labeling, batch release arrangements, and site GMP status for the Algerian supply chain, with particular attention to serialization, importation controls, and Arabic or French labeling alignment.

• Assessment and inspection reports from WHO PQ or stringent authorities, with manufacturer consent
• Current GMP certificates matching legal entities and activities for all sites in the supply chain
• Identical product composition, strength, and manufacturing sites to those assessed elsewhere
• Final labeling proofs and patient information in French consistent with relied-upon versions

The Laboratoire National de Contrôle des Produits Pharmaceutiques (LNCPP) is ANPP’s state quality-control laboratory. It operates to ISO/IEC 17025 principles and is pursuing WHO prequalification for national control laboratories. LNCPP conducts independent testing to verify compliance with the registered specifications, pharmacopoeial standards, and labeling claims. Triggers include first-batch releases, targeted risk-based sampling, post-import checks, complaint investigations, and surveillance programs.

Sponsors should anticipate requests for validated methods, reference standards, and stability data that support the claimed shelf life under Algeria’s climatic conditions. Where transferable methods are not available, equivalency protocols and verification reports may be required. Laboratory data must be traceable, contemporaneous, and complete; ISO/IEC 17025 principles and chain-of-custody practices should guide document preparation. For organizational readiness, see the structured checklist in ISO/IEC 17025 chemical-testing labs readiness.

ANPP treats laboratory investigations as an extension of the registered quality system. Confirmed failures trigger product holds and root-cause investigations consistent with Out-of-Spec handling. Sponsors should align their certificate-of-analysis formats to the registered specifications and be prepared to provide raw data and audit trails. Electronic laboratory management and release workflows—such as those provided by Lab QC—help standardize method execution, capture metadata, and accelerate review-by-exception without compromising data integrity.

ANPP regulates medical devices and IVDs under a risk-based framework influenced by international practice. Device families are classified by intended purpose and risk, with proportionate premarket scrutiny and post-market obligations. While CE certificates and EU technical documentation are persuasive, ANPP may request Algeria-specific labeling, Arabic or French instructions for use, and updated declarations that match the legal manufacturer supplying the Algerian market.

Technical documentation should be assembled as a coherent medical device classification and evidence package that includes clinical evaluation where required, cybersecurity and software lifecycle documentation for SaMD, and risk management consistent with ISO 14971. For software, IEC 62304 lifecycle controls and usability engineering aligned to international standards are expected, especially where clinical performance or safety is affected by the user interface.

Cosmetics and personal-care products fall within ANPP’s portfolio for market authorization, safety substantiation, and manufacturing oversight. The regulator expects Good Manufacturing Practices for cosmetics consistent with ISO 22716, with particular emphasis on micro-control, packaging compatibility, and claims substantiation. A complete product file should cover composition, purity of restricted substances, safety assessment, and labeling that meets Algerian language and ingredient-listing conventions.

Across devices, IVDs, and cosmetics, sponsors should map supply chains clearly, identify economic operators for Algeria, and align import documentation with registration particulars. Device incident reporting and field-safety corrective actions are coordinated with ANPP, ensuring traceability to affected lots and distribution records. Cosmetics adverse-event monitoring is also expected, with trend reviews integrated into quality management and periodic updates upon ANPP request.

Pharmacovigilance is coordinated nationally through the CNPM within ANPP’s framework, covering spontaneous adverse-event reporting, literature surveillance, periodic reports, and risk-minimization commitments. Holders of marketing authorizations must maintain local pharmacovigilance contacts and procedures to detect, assess, and report adverse events within internationally accepted timelines, with expedited reporting for serious, unexpected, or fatal cases.

Risk management plans submitted at approval are living documents. ANPP expects signal detection, benefit–risk evaluation, and targeted risk-minimization measures to be updated as new data emerge. Periodic safety update reports should be aligned to reference dates accepted by ANPP, and must detail cumulative exposure, important identified and potential risks, and ongoing or new pharmacovigilance studies. For devices and IVDs, materiovigilance procedures govern incident notifications, trend reporting, and field safety corrective actions.

ANPP encourages the use of standardized electronic formats aligned to ICH and international device reporting structures. Local language considerations apply to patient-facing communications, educational materials, and labeling updates. Companies should integrate CNPM requirements into a single governance system that links complaint handling, batch traceability, and recall decision-making to a documented post-market surveillance plan spanning medicines and devices.

ANPP requires a transparent price dossier that typically states the ex-factory price, pack configurations, and international reference data where applicable. Prices must be justified with cost structures consistent with Algerian rules and clearly mapped to the exact strength, dosage form, and pack size submitted for authorization. Currency conversions should be based on the reference dates requested by the authority, with supporting invoices and contracts that can be reconciled during review.

Import permissions are generally sequenced after MA grant, with product-specific licenses tied to the authorized presentation, the named importer, and the registered manufacturer list. Where samples are required for LNCPP testing, import permits should reference the same composition and labeling approved in the dossier. Any divergence between price files, labeling proofs, and GMP site lists triggers questions, clock stops, or rework that prolongs time to market.

• Submitting mixed-language dossiers where French administrative content conflicts with English technical modules
• Quoting ex-factory prices that do not reconcile to pack sizes, strength, or the invoicing unit in the application
• Using labeling proofs that differ from the declared active content, route, or medical claims
• Requesting import licenses before finalizing the MA’s legal manufacturer and importer particulars
• Omitting legalized GMP certificates or presenting certificates that do not match the legal entity and address
• Providing stability protocols that do not reflect Algeria’s climatic zone or registered packaging materials

V5 Ultimate operationalizes Algeria-ready compliance by centralizing controlled documents, training, and change control so teams can keep the administrative core, quality modules, and labeling synchronized. Structured workflows help authors manage French-language content, track price-file source data, and keep site lists, declarations, and letters of authorization internally consistent across submissions and renewals.

For manufacturing and laboratory operations, V5 standardizes method execution, sampling, data review, and deviation management, enabling rapid, defensible responses to LNCPP queries and ANPP inspections. Electronic batch records, supplier oversight, and release-by-exception reduce cycle time while improving data integrity. Integrated analytics, notifications, and audit trails anchor a continuous-improvement program that is inspection-ready by design.

Quality leaders can map risk controls to product files, post-market commitments, and vigilance actions in a single governed system. With configurable workflows and role-based access, V5 provides a reliable framework for dossier maintenance, serialization and import documentation alignment, and recall coordination—streamlining readiness for Algerian and international regulators alike. Explore QMS and Document Control to see how these capabilities come together in practice.